FORCING ( Dapagliflozin) Dapagliflozin Review, diabetes mellitus

Clinical and pharmacological group: Oral hypoglycemic drug Active substance dapagliflozin (dapagliflozin) Indications: Type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control as: monotherapy; combination therapy with metformin, sulfonylurea derivatives (incl. in combination with metformin), thiazolidinediones, dipeptidyl peptidase 4 inhibitors (DPP4) (incl. in combination with metformin), glucagonlike polypeptide1 receptor agonist (GLP1) exenatide of prolonged action in combination with metformin, insulin preparations (in incl. in combination with one or two hypoglycemic drugs for oral administration) in the absence of adequate glycemic control on this therapy; starting combination therapy with metformin, if this therapy is appropriate. Contraindications increased individual sensitivity to any component of the drug; type 1 diabetes mellitus; diabetic ketoacidosis; renal insufficiency with calculated GFR consistently less tha